ReviewDrugs2017
Triazole Resistance in Aspergillus Species: An Emerging Problem.
Review in Drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 155 citations in OpenAlex.
- Aspergillus fumigatus-a systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Molecular and Phenotypic Characterization of Multidrug-ResistantJournal of fungi (Basel, Switzerland) · 2026Article
- EneA of Aspergillus fumigatus is a regulator of secondary metabolism and enhances nscA expression in presence of polyenes and Streptomyces.Scientific reports · 2026Article
- Directed evolution of the pathogenic moldAntimicrobial agents and chemotherapy · 2026Article
- A One Health Perspective onJournal of fungi (Basel, Switzerland) · 2026Article
- Understanding multi-azole resistance inFrontiers in fungal biology · 2026Article
- Contribution of DNA Metabarcoding to the Environmental Fungal Assessments in Hospitals.Microbial ecology · 2025Article
- Impact of the use of azole fungicides, other than as human medicines, on the development of azole-resistantEFSA journal. European Food Safety Authority · 2025Article
- High prevalence of azole resistance among environmentalFrontiers in microbiology · 2025Article
- Comparison of Morphological, Virulence, and Antifungal Susceptibility Characteristics WithinInfection and drug resistance · 2025Article
- Critical insights on fungal contamination in schools: a comprehensive review of assessment methods.Frontiers in public health · 2025Review
- Aspergillus fumigatus escape mechanisms from its harsh survival environments.Applied microbiology and biotechnology · 2024Review
- Review and Current Perspectives on DNA Topoisomerase I and II Enzymes of Fungi as Study Models for the Development of New Antifungal Drugs.Journal of fungi (Basel, Switzerland) · 2024Review
- Filling the Knowledge Gap Regarding Microbial Occupational Exposure Assessment in Waste Water Treatment Plants: A Scoping Review.Microorganisms · 2024Article
- Azole resistance mechanisms and population structure of the human pathogenApplied and environmental microbiology · 2024Article
- Commercial Methods for Antifungal Susceptibility Testing of Saprophytic Molds: Can They Be Used to Detect Resistance?Journal of fungi (Basel, Switzerland) · 2024Review
- Importance of theJournal of fungi (Basel, Switzerland) · 2024Article
- Uncovering a NovelJournal of fungi (Basel, Switzerland) · 2024Article
- Isolation of triazole-resistantMycology · 2024Article
- Surveillance of Amphotericin B and Azole Resistance inJournal of fungi (Basel, Switzerland) · 2023Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus species are ubiquitous fungal saprophytes found in diverse ecological niches worldwide. Among them, Aspergillus fumigatus is the most prevalent and is largely responsible for the increased incidence of invasive aspergillosis with high mortality rates in some immunocompromised hosts. Azoles are the first-line drugs in treating diseases caused by Aspergillus spp. However, increasing reports in A. fumigatus azole resistance, both in the clinical setting and in the environment, are threatening the effectiveness of clinical and agricultural azole drugs. The azole target is the 14-α sterol demethylase encoded by cyp51A gene and the main mechanisms of resistance involve the integration of tandem repeats in its promoter and/or single point mutations in this gene. In A. fumigatus, azole resistance can emerge in two different scenarios: a medical route in which azole resistance is generated during long periods of azole treatment in the clinical setting and a route of resistance derived from environmental origin due to extended use of demethylation inhibitors in agriculture. The understanding of A. fumigatus azole resistance development and its evolution is needed in order to prevent or minimize its impact. In this article, we review the current situation of azole resistance epidemiology and the predominant molecular mechanisms described based on the resistance acquisition routes. In addition, the clinical implications of A. fumigatus azole resistance and future research are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.